Jagsonpal Pharmaceuticals opened at ₹225.58, in line with its previous close of ₹225.58. During today's session, the stock has traded between ₹219.80 and ₹229.80, with an average traded price of ₹224.15. It is currently showing a downward intraday trend.
An investment of ₹10,000 made 5 years ago in Jagsonpal Pharmaceuticals is now worth
₹ 36,194.00
giving a profit of
₹ 26,194.00 (261.94%)
Note: Past profits do not guarantee future returns.
No analyst rating data available.
Today's Change
-3.06 (-1.36%)
Day High
₹229.80
Day Low
₹219.80
Day Open
₹225.58
Prev Close
₹225.58
Volume
96,666
Value Traded
₹2.17 Cr
1W Return
-3.03%
1M Return
-4.45%
3M Return
-4.40%
6M Return
15.34%
1Y Return
0.78%
Market Cap (₹ Cr.)
1,468
PE Ratio
32.70
PB Ratio
5.41
Dividend Yield
1.77%
ROE
15.60%
ROCE
20.30%
Book Value (₹)
41.61
Face Value (₹)
2.00
EPS (TTM)
-
Industry PE
-
Beta
-
Debt to Equity
-
1 Week
-3.03%
6 Week
-
1 Month
-4.45%
3 Month
-4.40%
9 Month
24.38%
No data available.
Jagsonpal Pharmaceuticals completes acquisition of Group Pharma wellness portfolio
Jagsonpal Pharmaceuticals completed the acquisition of Group Pharmaceuticals' Wellness Portfolio on October 1, 2026. Upfront consideration stands at ₹23.7 crore, with an additional ₹23.0 crore contingent on FY28 sales. The acquired portfolio generated ₹24.6 crore in FY26 revenue with gross margins of 78.0%. Transaction includes two key brands covering six states and approximately 30,000 doctors. Company retains cash reserves of ~₹170 crore as of Q1FY27 to support future growth initiatives.
12 days agoJagsonpal Pharmaceuticals acquires Wellness Portfolio for up to ₹46.7 crore
Acquires Wellness Portfolio from Group Pharmaceuticals for up to ₹46.7 crore. Initial consideration of ₹23.7 crore payable on closing. Additional ₹23.0 crore linked to FY28 sales performance. Target portfolio generated ₹24.6 crore turnover in FY26.
20 days agoJagsonpal AGM results: All 5 resolutions approved by shareholders
Jagsonpal Pharmaceuticals passed all 5 resolutions at its 47th AGM held on September 18, 2026. Total votes polled ranged from 46.2 million to 49.2 million across different resolutions. Anil Kumar Matai appointed as Independent Director with 99.99% shareholder support. Reappointment of retiring director Prithpal Singh Kochar approved; relative's votes declared invalid. Cost auditor remuneration for FY27 ratified with near-unanimous approval.
22 days agoJagsonpal Pharmaceuticals Q4FY26 Results: Net profit up 19%, 200% dividend
Operating profit after tax grew 19% YoY to ₹446 crore in FY26. Revenue increased 6.9% to ₹2,872 crore with EBITDA margin at 21.2%. Board proposes 200% dividend including ₹1.50 special dividend per share. Company completed ₹40 crore share buyback at 40% premium to market price. Acquired 85% stake in Aequitas Healthcare for ₹20.8 crore.
1mo agoJagsonpal Pharmaceuticals submits FY26 BRSR with ESG disclosures
Jagsonpal Pharmaceuticals filed its FY26 BRSR report covering ESG metrics. Turnover reached ₹2,872.25 million with pharmaceutical formulations driving 99.42% of revenue. Employee count stands at 1,305 with 100% health insurance coverage for permanent staff. Waste disposal decreased to 39,122 kg from 43,070 kg in the previous year. Board diversity improved with 33% women representation among directors.
1mo agoJagsonpal Q1 Results: Net profit rises to ₹84.3 lakh, revenue up 44%
Jagsonpal Pharmaceuticals reported a Q1FY27 standalone net profit of ₹84.3 lakh, recovering from a ₹6.6 lakh loss in Q1FY25. Revenue surged 44% YoY to ₹2,000.6 lakh. The board recommended a final dividend of ₹4 per share, including a special payout, for FY26.
2mo ago| Stock | LTP | Change % | Market Cap (Cr.) | PE | 1Y Return |
|---|---|---|---|---|---|
| ₹1,770.70 | +0.61% | ₹4,24,850.24 | 34.83 | +5.97% | |
| ₹9,285.00 | -1.50% | ₹2,46,487.58 | 85.12 | +43.41% | |
| ₹4,642.90 | -0.84% | ₹1,76,600.99 | 82.55 | +31.42% | |
| ₹1,132.50 | -0.17% | ₹1,12,967.31 | 24.74 | +14.00% | |
| ₹2,059.40 | -0.47% | ₹1,11,271.90 | 102.63 | +134.89% | |
| ₹1,329.60 | +1.40% | ₹1,07,412.86 | 31.62 | -14.87% | |
| ₹1,240.00 | +0.86% | ₹1,03,500.36 | 32.26 | -1.93% | |
| ₹2,372.00 | -1.17% | ₹97,974.30 | 47.92 | -3.57% | |
| ₹1,684.60 | -1.31% | ₹96,928.16 | 26.40 | +49.04% | |
| ₹1,953.60 | +0.96% | ₹89,336.17 | 16.03 | -0.29% | |
| ₹2,265.30 | -0.78% | ₹63,932.35 | 35.82 | +16.81% | |
| ₹5,250.00 | +0.86% | ₹62,771.63 | 28.34 | -3.75% |
An investment of ₹10,000 made 5 years ago in Jagsonpal Pharmaceuticals is now worth
₹ 36,194.00
giving a profit of
₹ 26,194.00 (261.94%)
Note: Past profits do not guarantee future returns.
